Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Viewpoints: 'Triage' at the VA; GOP can't 'fix' health law; mental health problems in LA jail

Washington's attention span on the Veterans Affairs scandal seems to be expiring. Though 42 of the VA's 152 major campuses (27%) are still under investigation for falsifying wait-time records, the Senate is converging on a bipartisan deal that claims to solve the problem.

10 Jun 2014

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen, Inc. and the University of Colorado today announced exclusive license agreements that allow for Ocugen to continue developing two drug candidates for the treatment for ophthalmology indications, and that one of the assets, OCU100, recombinant lens epithelium derived growth factor 1-326 (LEDGF1-326), received orphan-drug status from the U.S. Food and Drug Administration for treatment of retinitis pigmentosa (RP), a rare eye disease.

6 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

Research to Prevent Blindness (RPB), the leading eye research foundation, is providing $500,000 to accelerate the development of treatments for Retinitis Pigmentosa (RP) -- a family of retinal diseases that progressively create extreme tunnel vision, loss of night vision and leave affected patients legally blind by the age of 40.

5 Jun 2014

CenterVue's next generation Macular Integrity Assessment receives FDA clearance

CenterVue, Inc., a leader in the design and manufacture of highly automated medical devices for the diagnosis and management of ocular pathologies, today announced FDA 510(k) clearance has been granted for the company's next generation Macular Integrity Assessment (MAIA).

4 Jun 2014

Medicare to pay for hep C screenings for baby boomers

The decision comes amid controversy surrounding the costs of new drugs to treat the blood-borne virus. Meanwhile, two studies find that Medicare could save billions if doctors switched from an expensive eye medication to a similar, much cheaper one and, also, if Part D plans were selected based on the actual drugs patients take.

4 Jun 2014

Diverse group of researchers to address eye healthcare problems of the 21st century

For an individual the loss of sight is estimated by the RNIB to have a financial impact of -20k per year and the annual cost to the UK economy is around -6.5 billion in terms of direct healthcare costs and other costs such as unpaid carers and loss of employment.

3 Jun 2014

First Edition: June 3, 2014

Today's headlines include coverage of Medicare data released Monday indicating that 2012 charges for some common inpatient hospital procedures dramatically increased over the previous year.

From Medtronic 3 Jun 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

Regular grape consumption may play role in eye health

New research presented this week at the Association for Research in Vision and Ophthalmology conference in Orlando, Florida suggests that regular grape consumption may play a role in eye health by protecting the retina from deterioration.

30 May 2014

Study shows high BP drugs may raise likelihood of age-related macular degeneration

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

29 May 2014

BioTime receives ISO 13485:2003 certification for development of BioTime HyStem hydrogels

BioTime, Inc. today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture, and distribution of BioTime HyStem® hydrogels for cell delivery applications.

28 May 2014

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

The Obama administration calls it an adjustment, Republicans call it a bailout and insurance companies call it the one thing that might keep them from raising rates and angering policyholders.

28 May 2014

Optegra top tips for healthy eyes this hayfever season

This year's hayfever season is upon us: the temperatures and pollen count start to rise, noses are beginning to run and eyes are starting to itch.

20 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting.

15 May 2014

Study reveals 70% of patients with diabetic retinopathy will develop macular edema

In Mexico, at least 14 million people have developed macular edema due to diabetes (DME), which like retinopathy affects central vision and can lead to blindness if not treated early .

13 May 2014

Monthly injections to counteract AMD may not be necessary, say researchers

Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary.

7 May 2014

BrightFocus Foundation honors 5 outstanding scientists in fields of macular degeneration, glaucoma

The BrightFocus Foundation today honored five outstanding scientists in the fields of macular degeneration and glaucoma, presenting them with named research awards at an event during the annual meeting of the Association for Research in Vision and Ophthalmology.

6 May 2014

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Researchers have failed to find a significant genotypic effect on ranibizumab treatment response in Korean patients with neovascular age-related macular degeneration.

1 May 2014

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Viewpoints: 'Triage' at the VA; GOP can't 'fix' health law; mental health problems in LA jail

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

CenterVue's next generation Macular Integrity Assessment receives FDA clearance

Medicare to pay for hep C screenings for baby boomers

Diverse group of researchers to address eye healthcare problems of the 21st century

First Edition: June 3, 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Regular grape consumption may play role in eye health

Study shows high BP drugs may raise likelihood of age-related macular degeneration

BioTime receives ISO 13485:2003 certification for development of BioTime HyStem hydrogels

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

Optegra top tips for healthy eyes this hayfever season

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Study reveals 70% of patients with diabetic retinopathy will develop macular edema

Monthly injections to counteract AMD may not be necessary, say researchers

BrightFocus Foundation honors 5 outstanding scientists in fields of macular degeneration, glaucoma

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in